Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53.
Cancer Cell Int. 2022 Dec 1;22(1):380. doi: 10.1186/s12935-022-02807-4.
Cancer Cell Int. 2022.
PMID: 36457011
Free PMC article.
Characterization of DNA damage response deficiency in pancreatic cancer patients from China.
Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L.
Zhang X, et al.
Cancer Commun (Lond). 2022 Jan;42(1):70-74. doi: 10.1002/cac2.12238. Epub 2021 Nov 24.
Cancer Commun (Lond). 2022.
PMID: 34821074
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite